Yield10 Bioscience Announces First Quarter 2017 Financial Results
May 11, 2017 20:06 pm UTC| Business
WOBURN, Mass., May 11, 2017 -- Yield10 Bioscience, Inc. (NASDAQ:YTEN) today reported financial results for the three months ended March 31, 2017. Yield10 Bioscience kicked off the year with new branding, reflecting the...
Selecta Biosciences Announces First Quarter 2017 Financial Results and Provides Corporate Update
May 11, 2017 20:06 pm UTC| Business
On Track to Complete Phase 2 Trial of Lead Product Candidate, SEL-212, in 2017Licensed LMB-100, a Clinical-Stage Candidate for Mesothelioma and Pancreatic Cancer, from the National Cancer Institute (NCI) Obtained Synthetic...
Selecta Biosciences Announces First Quarter 2017 Financial Results and Provides Corporate Update
May 11, 2017 20:06 pm UTC| Business
On Track to Complete Phase 2 Trial of Lead Product Candidate, SEL-212, in 2017Licensed LMB-100, a Clinical-Stage Candidate for Mesothelioma and Pancreatic Cancer, from the National Cancer Institute (NCI) Obtained Synthetic...
MasterCraft Reports Fiscal 2017 Third-Quarter and Year-To-Date Results
May 11, 2017 20:05 pm UTC| Business
VONORE, Tenn., May 11, 2017 -- MasterCraft(NASDAQ:MCFT) today announced financial results for its fiscal 2017 third quarter ended April 2, 2017. Highlights: Net sales for the third quarter increased to $58.5 million,...
MasterCraft Reports Fiscal 2017 Third-Quarter and Year-To-Date Results
May 11, 2017 20:06 pm UTC| Business
VONORE, Tenn., May 11, 2017 -- MasterCraft(NASDAQ:MCFT) today announced financial results for its fiscal 2017 third quarter ended April 2, 2017. Highlights: Net sales for the third quarter increased to $58.5 million,...
Cyclacel Pharmaceuticals Reports First Quarter 2017 Financial Results
May 11, 2017 20:05 pm UTC| Business
BERKELEY HEIGHTS, N.J., May 11, 2017 -- Cyclacel Pharmaceuticals, Inc. (NASDAQ:CYCC) (NASDAQ:CYCCP) ("Cyclacel" or the "Company") a biopharmaceutical company developing oral therapies that target the various phases of...
May 11, 2017 20:05 pm UTC| Business
SAN DIEGO, May 11, 2017 -- TRACON Pharmaceuticals (NASDAQ:TCON), a clinical stage biopharmaceutical company focused on the development and commercialization of novel targeted therapeutics for cancer, wet age-related...